MedPath

Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-
Clinical Trials
Related News
expresspharma.in
·

Wanbury announces new API product portfolio and launch plans

Wanbury launches new API portfolio for FY24-25, including high-demand products like Metformin HCl, Sertraline HCl, and Diphenhydramine HCl. The company plans regulatory filings for USDMF and CEP, aligning with USP, Ph. Eur., and BP standards to meet global pharmaceutical needs.
springermedizin.de
·

Multimodal Analgesia Approach in Acute Low Back Pain Management: A Phase III Study

A study evaluated the efficacy and safety of etoricoxib 90 mg/tramadol 50 mg (QD) versus paracetamol 325 mg/tramadol 37.5 mg (TID) for acute low back pain. Results showed etoricoxib/tramadol provided superior pain relief and functional improvement, with a lower incidence of adverse events and opioid-sparing effects, suggesting it as a beneficial therapeutic option.
medicalxpress.com
·

Diabetes drug helps the immune system recognize reservoirs of HIV, study discovers

Metformin, a type 2 diabetes drug, may help deplete HIV reservoirs and eliminate the virus in patients on antiretroviral therapy, according to a study by Canadian researchers. The drug inhibits mTOR activity, slowing HIV replication and overexpressing BST2 protein to aid immune system recognition and targeting of infected cells.
mdpi.com
·

Current Approaches for the Prevention and Treatment of GVHD

GVHD, a major complication post-allogeneic HSCT, involves acute (aGVHD) and chronic (cGVHD) forms, with distinct inflammatory and autoimmune/fibrotic features, respectively. Prevention strategies include CNI with MTX or MMF, ATG, PTCy, and graft manipulation. First-line treatment for aGVHD is corticosteroids, with Ruxolitinib for steroid-refractory cases. cGVHD treatment focuses on symptom control and preventing progression, with ECP and Ruxolitinib as options. Research highlights the importance of microbiota, biomarkers, and novel therapies targeting immune and non-immune pathways for improved outcomes.
techbullion.com
·

Navigating the Biotech Boom: Career Prospects and Emerging Fields in Life Sciences

The life sciences sector is booming with opportunities in biotechnology, driven by innovations in genetics, pharmaceuticals, and agricultural sciences. Emerging fields like synthetic biology, personalized medicine, and bioinformatics offer dynamic career paths. Investing in biotech requires careful research and diversification, while ethical considerations and challenges must be navigated responsibly. The industry promises a future of groundbreaking discoveries and fulfilling careers.
frontiersin.org
·

The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in ...

The UPS regulates PD-1/PD-L1 expression and function, influencing immune cells in the TIME, including T cells, DCs, and TAMs, to modulate tumor immune evasion. E3 ligases and DUBs play crucial roles in this process, offering potential targets for cancer immunotherapy.

Related Clinical Trials:

A Study of VLX1570 and Dexamethasone in Myeloma Patients
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
thirdeyenews.in
·

Gene Panel Market Size, Top Manufacturers, Growth Factors and Regions Forecast 2024-2032

The gene panel market is expected to grow from USD 3660.09 Million in 2024 to USD 14408.16 Million by 2031, driven by advancements in genomic technologies, personalized medicine, and increasing demand for cancer panels. Key technologies include Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) panels. Market growth is also supported by rising awareness of genetic testing in regions like North America and Asia-Pacific.
springermedizin.de
·

Different Models, Same Results: Considerations When Choosing Between Approaches to Assess Cost-Effectiveness of CAR-T Therapies

Article compares three modelling approaches (PSM, DES, STM) for assessing cost-effectiveness of CAR-T therapies in young patients with r/r ALL, finding minor variations in results due to different modelling approaches, with DES generating the most LYs and QALYs for tisagenlecleucel. Sensitivity analysis shows cost-effectiveness most impacted by cure-point assumption, duration of IVIg use, and CAR-T wait time, with DES being the only structure allowing for wait time testing. Checklist developed to summarize criteria captured by each model type, emphasizing DES's ability to incorporate complex treatment pathways and individual patient history.
market.us
·

Lab on a Chip Market Size, Share | CAGR Of 9.5%

The Lab on a Chip Market is projected to grow from USD 6.2 billion in 2023 to USD 15.4 billion by 2033, at a CAGR of 9.5%. This growth is driven by advancements in microfluidic technology, increasing demand for point-of-care diagnostics, and the rising prevalence of chronic diseases. North America leads the market, with significant contributions from genomics and proteomics in cancer research. The Asia Pacific region is expected to experience the highest growth rate, fueled by healthcare advancements and government investments.
jeevatrials.com
·

CAR-T To N-of-1 Studies: How Jeeva Is Helping Drive Trial Efficiency and Inclusivity

Jeeva Clinical Trials Inc, led by CEO Dr. Harsha Rajasimha, offers a unified AI-driven platform simplifying clinical trials by automating tasks, enhancing patient engagement, and reducing reliance on multiple point solutions. It aims to improve efficiency, especially in complex oncology trials, by integrating data management, patient engagement, and decentralized tools. Jeeva's technology supports diverse patient participation, including remote eConsent and language translation, addressing underrepresentation in clinical research. The platform also aids in CAR-T studies and N-of-1 trials, emphasizing inclusivity and efficiency in clinical trial management.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy